Phibro Animal Health (PAHC)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$38.25-0.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · PAHC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On August 26, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fourth quarter and fiscal year ended June 30, 2026 and its financial guidance for the fiscal year ending June 30, 2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be dee…
OTHER EVENTS On July 28, 2026, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 23, 2026, to stockholders of record at the close of business on September 2, 2026. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Chief Executive Officer and President — Daniel (Dani) Bendheim: Daniel Bendheim was promoted to Chief Executive Officer and President with a new employment agreement and equity award.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On May 6, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended March 31, 2026 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” f…
OTHER EVENTS On May 5, 2026, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 24, 2026, to stockholders of record at the close of business on June 3, 2026. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. As discussed in
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On April 28, 2026, Phibro Animal Health Corporation (the “Company”) entered into Amendment No. 1 to its Credit Agreement (“Amendment No. 1”) with Coöperatieve Rabobank U.A., New York Branch, as administrative agent, collateral agent and L/C issuer, and each lender from time to time party thereto, which amends the Credit Agreement, dated as of July 3, 2024, among the Company, Coöperatieve Rabobank U.A., New York Branch, as administrative agent, colla…
Director — Ms. Joyce J. Lee: Ms. Joyce J. Lee resigned from her position as Director of the Company.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 4, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “…
OTHER EVENTS On February 3, 2026, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 25, 2026, to stockholders of record at the close of business on March 4, 2026. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
CEO — Jack C. Bendheim: The CEO is transitioning to Executive Chairman while a named internal successor (his son) assumes the role, representing an orderly succession rather than a loss of leadership.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 5, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be…
OTHER EVENTS On November 4, 2025, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 17, 2025, to stockholders of record at the close of business on November 26, 2025. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On August 27, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fourth quarter and fiscal year ended June 30, 2025 and its financial guidance for the fiscal year ending June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be dee…
OTHER EVENTS On July 29, 2025, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 24, 2025, to stockholders of record at the close of business on September 3, 2025. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On May 7, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended March 31, 2025 and its financial guidance for the fiscal year ending June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” f…
OTHER EVENTS On May 6, 2025, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on June 25, 2025, to stockholders of record at the close of business on June 4, 2025. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On February 5, 2025, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended December 31, 2024 and its financial guidance for the fiscal year ending June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “…
OTHER EVENTS On February 4, 2025, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on March 26, 2025, to stockholders of record at the close of business on March 5, 2025. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Director — Joyce J. Lee: The filing discloses the appointment of a new independent director to the board, which is a routine governance event and not a departure of a senior executive.
President — Rob Aukerman: The President of the North America Region is retiring with a named internal successor and an advisory transition period, indicating an orderly succession rather than a sudden loss.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 6, 2024, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2024 and its financial guidance for the fiscal year ending June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be…
OTHER EVENTS On November 5, 2024, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 18, 2024, to stockholders of record at the close of business on November 27, 2024. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT. On October 31, 2024, in connection with the completion of the acquisition of the Purchased Business, Phibro borrowed $350 million under its Credit Agreement, dated as of July 3, 2024, comprised of $189 million of Delayed Draw Term A-1 Loans and $161 million of Delayed Draw Term A-2 Loans. The foregoing description of the Credit Agreement is qualified in its entirety by reference…
COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS. On October 31, 2024, Phibro Animal Health Corporation, a Delaware corporation (the “Company”) and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of the Company (together with the Company, “Phibro”), completed the acquisition of the medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”) of Zoetis Inc., a Delaware corporation (“Zoetis”), pursua…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.